COG.L

Cambridge Cognition Holdings Plc
Cambridge Cognition - Result of AGM & Change of Name of NOMAD & Broker
28th June 2024, 12:48
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4101U
Cambridge Cognition Holdings PLC
28 June 2024
 

Cambridge Cog_U.K Header AW.jpg

28 June 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")


Result of AGM

Change of Name of Nominated Adviser and Joint Broker

 

Cambridge Cognition plc (AIM: COG), which develops and markets digital solutions to assess brain health, held its Annual General Meeting ("AGM") earlier today at the registered office of the Company; Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25 9TU and announces that all resolutions put forward were duly passed.

 

Proxy votes were received in respect of approximately 55% of the Company's issued share capital and the votes cast were as follows:

 

Resolution

For

 

Against

 

Withheld

1 - to approve the 2023 report and accounts

22,321,648

99.98%

5,003

0.02%

642,810

2 - to appoint the auditors

22,930,519

99.96%

8,503

0.04%

30,439

3 - to authorise the directors to set the auditors remuneration

22,942,198

99.98%

5,003

0.02%

22,260

4 - to re-elect Richard Bungay as a director

20,756,611

98.92%

226,842

1.08%

1,986,008

5 - to elect Nick Rodgers as a director

22,927,961

99.82%

40,492

0.18%

1,008

6 - to elect Stuart Gall as a director

22,927,961

99.82%

40,492

0.18%

1,008

7 - authority to allot shares

22,798,499

99.26%

169,954

0.74%

1,008

8 - disapplication of pre-emption rights

22,789,981

99.22%

178,472

0.78%

1,008

9 - disapplication of pre-emption rights in connection with an acquisition or specified capital investment

22,788,299

99.22%

180,154

0.78%

1,008

 

Change of Name of Nominated Adviser and Broker

 

The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

 

Enquiries

 

Cambridge Cognition Holdings plc

Matthew Stork, Chief Executive Officer

Stephen Symonds, Chief Financial Officer

 

www.cambridgecognition.com

Tel: 01223 810 700

 

Panmure Liberum Limited (NOMAD & Joint Broker)

Freddy Crossley / Emma Earl / Mark Rogers

Rupert Dearden

Tel: 020 78862500

(Corporate Advisory)

(Corporate Broking)

 

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

(Corporate Broking)

Hudson Sandler (Financial PR and IR)

Dan de Belder / Hattie Dreyfus

Tel: 020 7796 4133

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company marketing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGDZGZVZRNGDZM]]>
TwitterFacebookLinkedIn